132 related articles for article (PubMed ID: 38532756)
21. A case report of the sustained and rapid response of bevacizumab in a TP53-positive breast cancer and liver metastatic patient through personalized medicine.
Eskandarion MR; Tizmaghz Z; Andalib B; Parsa N; Emami SAH; Shahsiah R; Oghabian MA; Shirkoohi R
Front Oncol; 2022; 12():940678. PubMed ID: 36119510
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor Cells in Breast Cancer Patients.
Hall C; Valad L; Lucci A
Crit Rev Oncog; 2016; 21(1-2):125-39. PubMed ID: 27481009
[TBL] [Abstract][Full Text] [Related]
24. Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer.
Roßwag S; Cotarelo CL; Pantel K; Riethdorf S; Sleeman JP; Schmidt M; Thaler S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920089
[TBL] [Abstract][Full Text] [Related]
25. Identification of frequent somatic mutations in inflammatory breast cancer.
Matsuda N; Lim B; Wang Y; Krishnamurthy S; Woodward W; Alvarez RH; Lucci A; Valero V; Reuben JM; Meric-Bernstam F; Ueno NT
Breast Cancer Res Treat; 2017 Jun; 163(2):263-272. PubMed ID: 28243898
[TBL] [Abstract][Full Text] [Related]
26. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
27. LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Ramirez-Ardila DE; Ruigrok-Ritstier K; Helmijr JC; Look MP; van Laere S; Dirix L; Berns EM; Jansen MP
Mol Oncol; 2016 Oct; 10(8):1363-73. PubMed ID: 27491861
[TBL] [Abstract][Full Text] [Related]
28. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
29. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer.
Zhou D; Ouyang Q; Liu L; Liu J; Tang Y; Xiao M; Wang Y; He Q; Hu ZY
Transl Oncol; 2019 May; 12(5):764-774. PubMed ID: 30893632
[TBL] [Abstract][Full Text] [Related]
31. Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer.
Lan J; Zhou YH; Zhang MX; Chen DQ; Wu MY; Yu ZY
Gland Surg; 2022 Feb; 11(2):319-329. PubMed ID: 35284312
[TBL] [Abstract][Full Text] [Related]
32. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Loibl S; Treue D; Budczies J; Weber K; Stenzinger A; Schmitt WD; Weichert W; Jank P; Furlanetto J; Klauschen F; Karn T; Pfarr N; von Minckwitz G; Möbs M; Jackisch C; Sers C; Schneeweiss A; Fasching PA; Schem C; Hummel M; van Mackelenbergh M; Nekljudova V; Untch M; Denkert C
Clin Cancer Res; 2019 Jul; 25(13):3986-3995. PubMed ID: 30979740
[TBL] [Abstract][Full Text] [Related]
33. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
Fuentes-Antrás J; Martínez-Rodríguez A; Guevara-Hoyer K; López-Cade I; Lorca V; Pascual A; de Luna A; Ramírez-Ruda C; Swindell J; Flores P; Lluch A; Cescon DW; Pérez-Segura P; Ocaña A; Jones F; Moreno F; García-Barberán V; García-Sáenz JÁ
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511178
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.
Bock C; Rack B; Kuhn C; Hofmann S; Finkenzeller C; Jäger B; Jeschke U; Doisneau-Sixou SF
Transl Oncol; 2012 Dec; 5(6):475-85. PubMed ID: 23323159
[TBL] [Abstract][Full Text] [Related]
36. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
39. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
[TBL] [Abstract][Full Text] [Related]
40. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
Callens C; Driouch K; Boulai A; Tariq Z; Comte A; Berger F; Belin L; Bièche I; Servois V; Legoix P; Bernard V; Baulande S; Chemlali W; Bidard FC; Fourchotte V; Salomon AV; Brain E; Lidereau R; Bachelot T; Saghatchian M; Campone M; Giacchetti S; Zafrani BS; Cottu P
Genome Med; 2021 Mar; 13(1):44. PubMed ID: 33722295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
